Insulin-producing cells injected into a man with type 1 diabetes have survived for a month so far without the need for immune ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

In type 2 diabetes, the body's ability to release insulin is impaired, which leads to high blood glucose levels. Research led ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

Type 1, which usually starts in childhood, and Type 2, which is more common in adults and linked to obesity. But researchers now know that not all Type 2 diabetes cases are the same. People with Type ...

Diabetes has long been lumped into two categories - Type 1, which often appears in childhood, or Type 2, which is associated with obesity and typically develops later in life. But scientists have ...

Sana (SANA) shares rallied 270% post-market on positive results from a study of its pancreatic cell transplant therapy UP421 in the treatment of type 1 diabetes. Read more here.

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...